Skip to main content

Table 3 Age-related, gender-, and treatment-stratified effect sizes of significant SNPs associated with EAA among different data sets

From: Genome-wide association studies identify novel genetic loci for epigenetic age acceleration among survivors of childhood cancer

GWAS

SNP

Population

−

Effect size

(SE)

P

Phet

I2 (%)

EAA-Horvath

rs732314

survivors (SJLIFE1) <18 Y

70

0.96

0.50

6.16E−02

  

survivors (SJLIFE2) <18 Y

314

0.97

0.25

1.27E−04

  

survivors (combined) <18 Y

384

0.97

0.22

1.52E−05

0.98

0.00

survivors (SJLIFE1) ≥18 Y

2066

0.51

0.10

1.14E−07

  

survivors (SJLIFE2) ≥18 Y

188

0.51

0.26

5.04E−02

  

survivors (combined) ≥18 Y

2254

0.51

0.09

1.39E−08

1.00

0.00

survivors (SJLIFE1) male

1132

0.46

0.13

3.92E−04

  

survivors (SJLIFE2) male

267

0.79

0.25

1.71E−03

  

survivors (combined) male

1399

0.53

0.11

3.94E−06

0.24

28.57

survivors (SJLIFE1) female

1004

0.54

0.14

2.10E−04

  

survivors (SJLIFE2) female

235

0.84

0.30

5.04E−03

  

survivors (combined) female

1239

0.60

0.13

4.58E−06

0.35

0.00

survivors (SJLIFE1) trunk-RT_Yes

649

0.37

0.17

3.47E−02

  

survivors (SJLIFE2) trunk-RT_Yes

91

0.03

0.39

9.39E−01

  

survivors (combined) trunk-RT_Yes

740

0.31

0.16

4.99E−02

0.42

0.00

survivors (SJLIFE1) trunk-RT_No

1487

0.56

0.12

1.30E−06

  

survivors (SJLIFE2) trunk-RT_No

411

0.91

0.22

3.46E−05

  

survivors (combined) trunk-RT_No

1898

0.64

0.10

3.88E−10

0.16

49.83

EAA-Hannum

rs28366133

survivors (SJLIFE1) <18 Y

70

0.17

0.73

8.20E−01

  

survivors (SJLIFE2) <18 Y

314

1.13

0.27

5.17E−05

  

survivors (combined) <18 Y

384

1.01

0.26

8.80E−05

0.21

35.12

survivors (SJLIFE1) ≥18 Y

2066

0.80

0.14

2.54E−08

  

survivors (SJLIFE2) ≥18 Y

188

0.28

0.40

4.78E−01

  

survivors (combined) ≥18 Y

2254

0.74

0.13

3.69E−08

0.23

32.01

survivors (SJLIFE1) male

1131

0.74

0.19

1.40E−04

  

survivors (SJLIFE2) male

267

0.91

0.32

4.43E−03

  

survivors (combined) male

1398

0.79

0.17

1.97E−06

0.64

0.00

survivors (SJLIFE1) female

1005

0.77

0.20

1.39E−04

  

survivors (SJLIFE2) female

235

0.71

0.33

3.47E−02

  

survivors (combined) female

1240

0.76

0.17

1.23E−05

0.87

0.00

survivors (SJLIFE1) chest-RT_Yes

608

0.72

0.27

6.89E−03

  

survivors (SJLIFE2) chest-RT_Yes

83

0.84

0.71

2.41E−01

  

survivors (combined) chest-RT_Yes

691

0.74

0.25

3.14E−03

0.88

0.00

survivors (SJLIFE1) chest-RT_No

1528

0.77

0.16

2.48E−06

  

survivors (SJLIFE2) chest-RT_No

419

0.88

0.24

3.02E−04

  

survivors (combined) chest-RT_No

1947

0.80

0.14

2.56E−09

0.70

0.00

  1. Abbreviations: GWAS Genome-wide association study, EAA Epigenetic age acceleration, Chr Chromosome, SE Standard error, N Number of samples, survivor (SJLIFE1) The first discovery data set of 2138 survivors included in our previously published study (ref. [6]), survivor (SJLIFE2) The second discovery data set of 502 children and adolescent survivors, survivors (combined) A combined set (meta-GWAS analysis) of the two discovery data sets (SJLIFE1 and SJLIFE2), trunk-RT Chest/abdominal/pelvic radiation therapy, chest-RT Chest radiation therapy